AbbVie Inc. (ABBV) FY2026 Q1 P&L / Income Statement

AbbVie Inc. (ABBV) FY2026 Q1 P&L / Income Statement

Income statement for 2026-01-01 through 2026-03-31. View: Key Product Portfolio by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net revenues

15,002,000,000 US dollars

Cost of products sold

4,218,000,000 US dollars

Gross profit (calculated)

10,784,000,000 US dollars

Operating expenses (calculated)

6,794,000,000 US dollars

Operating earnings

3,990,000,000 US dollars

Other income (expense), net (calculated)

negative 2,951,000,000 US dollars

Earnings before income tax expense

1,039,000,000 US dollars

Income tax expense

342,000,000 US dollars

Net earnings

697,000,000 US dollars

Aesthetics - Botox Cosmetic

668,000,000 US dollars

Aesthetics - Juvederm Collection

232,000,000 US dollars

Aesthetics - Other Aesthetics

286,000,000 US dollars

Immunology - Humira

688,000,000 US dollars

Immunology - Rinvoq

2,119,000,000 US dollars

Immunology - Skyrizi

4,483,000,000 US dollars

Neuroscience - Botox Therapeutic

1,009,000,000 US dollars

Neuroscience - Other Neuroscience

125,000,000 US dollars

Neuroscience - Qulipta

296,000,000 US dollars

Neuroscience - Ubrelvy

339,000,000 US dollars

Neuroscience - Vraylar

905,000,000 US dollars

Neuroscience - Vyalev

201,000,000 US dollars

Oncology - Elahere

198,000,000 US dollars

Oncology - Epkinly

83,000,000 US dollars

Oncology - Imbruvica

556,000,000 US dollars

Oncology - Venclexta

770,000,000 US dollars

Other Key Products - Linzess

283,000,000 US dollars

Other Key Products - Mavyret

351,000,000 US dollars

Undisclosed (calculated)

1,410,000,000 US dollars

Selling, general and administrative

3,578,000,000 US dollars

Research and development

2,472,000,000 US dollars

Acquired IPR&D and milestones

744,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to AbbVie Inc.: $695.00 M; to noncontrolling interests: $2.00 M.